Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6533
    +0.0009 (+0.14%)
     
  • OIL

    83.90
    +0.33 (+0.39%)
     
  • GOLD

    2,345.10
    +2.60 (+0.11%)
     
  • Bitcoin AUD

    97,504.18
    -1,111.36 (-1.13%)
     
  • CMC Crypto 200

    1,323.89
    -72.65 (-5.20%)
     
  • AUD/EUR

    0.6105
    +0.0032 (+0.53%)
     
  • AUD/NZD

    1.0992
    +0.0034 (+0.31%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,747.87
    +317.37 (+1.82%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,304.93
    +219.13 (+0.58%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Company News for May 11, 2023

  • Shares of Vishay Intertechnology, Inc. (VSH) surged 16.8% after the company reported first-quarter 2023 earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.57 per share.

  • Coherent Corp.’s (COHR) shares fell 5% after the company reported third-quarter fiscal 2023 earnings of $0.58 per share, missing the Zacks Consensus Estimate of $0.81 per share.

  • Shares of ICL Group Ltd (ICL) jumped 6% after the company reported first-quarter 2023 earnings of $0.23 per share, surpassing the Zacks Consensus Estimate of $0.19 per share.

  • Amicus Therapeutics, Inc.’s (FOLD) shares tumbled 5% after the company reported first-quarter 2023 loss of $0.18 per share, wider the Zacks Consensus Estimate of a loss of $0.13 per share.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report

Vishay Intertechnology, Inc. (VSH) : Free Stock Analysis Report

Coherent Corp. (COHR) : Free Stock Analysis Report

ICL Group Ltd. (ICL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research